Found 17 Amyloidosis trials
A listing of Amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine …
We plan to enroll up to 25 (target of 20 fully evaluable) adult subjects in this study who have an established diagnosis of advanced cardiac amyloidosis (AL). Subjects will be included in 2 subject cohorts of approximately 10 subjects each. In one cohort positron emission tomography/computed tomography (PET/CT) imaging will …
New treatments that target the protein tau are beginning to enter human clinical trials. While tau-related therapies hold great promise for AD, clinical trials focusing on pure tauopathies are appealing because these diseases do not exhibit concurrent amyloid pathology. Pure 4 microtubule binding repeat (4R) tauopathies (4RT) include corticobasal degeneration …
This research study is being done at the request of the US Food & Drug Administration (FDA) to collect additional safety information for the commercially available drug TEGSEDI. This research study is being conducted to examine any changes in health or side effects occurring within 24 hours following treatment with …
Are you having any trouble with your memory or sleep?This research study will explore whether treating sleep apnea can improve memory. Compensation is up to $300 for the participant's time and up to $100 for the study partner.
This registry is a retrospective observational, multi-center study designed to collect data and analyze data retrospectively on patients with AL or TTR cardiac amyloidosis. Subjects under the care of the local investigator will be identified and consented. No patient visits or patient procedures will be required for the purpose of …
11 - 17 of 17
- 1
- 2
